InhibRx

28 articles about InhibRx

• Inhibrx Announces Participation in Upcoming Investor Conference - Sep 13, 2021

  9/13/2021

  Inhibrx, Inc., a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, announced that the Company will be presenting at the following upcoming virtual investor conference.

• Inhibrx Reports Second Quarter 2021 Financial Results

  8/9/2021

  Inhibrx, Inc., a biotechnology company with four clinical programs in development, reported financial results for the second quarter of 2021.

• Inhibrx Initiates a Potential Registration-Enabling Phase 2 Study of INBRX-109 in Conventional Chondrosarcoma Patients, Updates Data for Ongoing Phase 1 Study and Announces Amended Loan Agreement with Oxford

  6/21/2021

  Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development, announced initiation of a potential registration-enabling Phase 2 study of INBRX-109 in conventional chondrosarcoma.

• Inhibrx Announces Participation in Upcoming Investor Conferences

  5/17/2021

  Inhibrx, Inc. (NASDAQ: INBX), a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, announced today that the Company will be presenting at the following upcoming virtual investor conferences:

• Inhibrx Reports First Quarter 2021 Financial Results

  5/13/2021

   Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development, today reported financial results for the first quarter of 2021.

• Inhibrx Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Announces Phase 1 Single Agent Dose Escalation Results for INBRX-105, a Novel Targeted 4-1BB Agonist

  3/12/2021

  Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development, today reported financial results for the fourth quarter and fiscal year 2020, and announced results from the single agent dose escalation of the Phase 1 study of INBRX-105.

• Inhibrx Announces Participation in Upcoming Investor Conference

  2/1/2021

  Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, announced today that the Company will be presenting at the following upcoming virtual investor conference

• Inhibrx Announces Phase 1 Dose Escalation Results of INBRX-106, a Novel Hexavalent OX40 Agonist

  1/5/2021

   Inhibrx, Inc. (Inhibrx), a clinical-stage biotechnology company with a broad pipeline of biotherapeutics in development, announced today results from Part 1 of the Phase 1 dose escalation trial of INBRX-106, a novel hexavalent OX40 agonist, in development for the treatment of solid tumors.

• Arecor's Partner Inhibrx Exercises Its Option to License a New Formulation Developed by Arecor in Accordance With the Terms of Formulation Development AgreementARESTAT™ formulated product progressing into clinical trial

  12/17/2020

  Arecor Ltd announces that its partner, Inhibrx, Inc., has exercised an option to license a novel enhanced formulation of Inhibrx's proprietary therapeutic candidate, INBRX-101, developed by Arecor using the Company's patented technology, Arestat™.

• Inhibrx Reports Financial Results for the Third Quarter 2020 and Announces Amended Loan Agreement with Oxford

  11/13/2020

  Successful completion of initial public offering with net proceeds of $126 million; cash and cash equivalents of $128 million as of September 30th

• Inhibrx Announces Positive Interim Results from the Phase 1 Trial of INBRX-109 in Chondrosarcoma Patients

  11/11/2020

  Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development, announced updated interim results today from a Phase 1 clinical trial evaluating the efficacy and safety of INBRX-109 in patients with chondrosarcoma.

• Inhibrx Announces Participation in Upcoming Investor and Scientific Conferences - Nov 05, 2020

  11/5/2020

  Inhibrx, Inc., a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, announced that the Company will be presenting at the following upcoming virtual investor and scientific conferences:

• Oxford Finance Announces $10 Million Credit Facility with Inhibrx, Inc.

  8/25/2020

  Oxford Finance LLC, a specialty finance firm that provides senior debt to life sciences and healthcare services companies worldwide, has announced that on July 15, 2020, it closed a $10 million senior secured term loan with Inhibrx, Inc., a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates.

• Inhibrx Announces Closing of Initial Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

  8/21/2020

  Inhibrx, Inc. ("Inhibrx") (Nasdaq: INBX), a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, today announced the closing of its previously announced initial public offering of 8,050,000 shares of common stock,

• Inhibrx Announces Dosing of First Patient in Phase 1 Dose-Escalation Study of INBRX-106, a Novel Hexavalent Agonist of OX40

  1/8/2020

  Inhibrx, Inc. (Inhibrx), a clinical-stage biotechnology company with a broad pipeline of biotherapeutics in development, announced today the administration of the first dose of INBRX-106 in a Phase 1 dose-escalation clinical study.

• Inhibrx Announces Enrollment of First Patient in Phase 1 Study of INBRX-101, a Modified Recombinant Human AAT-Fc Fusion Protein

  9/4/2019

   Inhibrx, Inc. (Inhibrx), a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, announced today the enrollment of the first patient in a Phase 1 clinical trial of INBRX-101 (NCT03815396).

• Inhibrx Reports Phase 1 Dose Escalation Results of INBRX-109, a Multivalent Agonist of Death Receptor 5

  9/3/2019

  Inhibrx, Inc. (Inhibrx), a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, announced today the completion of the dose escalation portion of its Phase 1 clinical trial of INBRX-109.

• Inhibrx Announces Option Agreement for Development and Commercialization of INBRX-101 (AAT-Fc) Outside of the United States and Canada with Chiesi Group

  5/30/2019

  Up to $162.5M in upfront, cost sharing and milestone payments, and escalating royalties into the high teens assuming exercise of the option

• Inhibrx Announces $40M Investment from Viking Global Investors

  5/21/2019

  Inhibrx, Inc. announced that it has entered into an agreement with Viking Global Investors LP for the offering and sale of convertible promissory notes in a private placement transaction in the aggregate principal amount of $40 million.

• Inhibrx Announces Dosing of First Patient in Phase 1 Dose-Escalation Study of INBRX-105, a Novel Multispecific PD-L1 and 4-1BB Antibody

  2/19/2019

  Inhibrx, Inc., a clinical-stage biotechnology company developing a broad pipeline of novel biologic therapeutic candidates, announced that dosing has begun in a Phase 1 dose-escalation clinical trial of INBRX-105.